Wild type p53-independent induction of apoptosis, coupled with downregulation of factors with well-established roles in tumor progression and metastasis by HEXIM117,41, makes re-expression of HEXIM1 via DNMT1 inhibitors an attractive anticancer strategy. Here, HEXIM1 is linked to neoplasm.